Quantcast

Industry news that matters to you.  Learn more

Mount Sinai Researchers Develop New Computational Method to Aide Analysis of Gene Expression Experiments

Researchers from Mount Sinai School of Medicine have developed a new computational method that will help streamline the analysis of gene expression experiments and provide scientists with a better mechanistic understanding of the differences between diseased and normal cells. The new database and software, called ChIP Enrichment Analysis (ChEA), will revolutionize how researchers identify drug targets and biomarkers. Researchers can find the tool online at http://amp.pharm.mssm.edu/lib/chea.jsp. The data are published in Bioinformatics.

ProxiScan Completes First Animal Tests

The first animal studies made using a 2009 R&D 100 Award-winning technology were recently performed at Molecular Insight Pharmaceuticals (MIP) in Cambridge, Mass. A new small molecule drug, Trofex, was successfully tested for its effectiveness as a biomarker for the detection of prostate cancer.

Immunogenicity Testing Proves Invaluable

Immunogenicity is a measure of the immune response to a biotherapeutic drug. It is a very relevant issue affecting not only the use of therapeutic protein drugs such as mAbs but also peptides, enzymes, cytokines, growth factors, recombinant proteins, and other biological products.

Micropatch Detects Disease Biomarkers in Skin

Scientists in Australia have built a microneedle device capable of detecting disease-specific proteins directly from the skin.

Biomarkers Changing Clinical Medicine

The pace of biomarker development is accelerating as investigators report new studies on cancer, diabetes, Alzheimer disease, and other conditions in which the evaluation and isolation of workable markers is prominently featured. CHI’s “ADAPT” meeting, to be held later this month, will profile various new strategies being developed by both the academic and private sectors.